MedTrace Logo

Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer

NCT01938105 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-09-26

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility and efficacy of preoperative nimotuzumab injection combined with concurrent chemoradiotherapy for initially inoperable, locally advanced cervical cancer.

Conditions

  • Locally Advanced Cervical Cancer

Interventions

OTHER

Nimotuzumab+chemoradiotherapy

Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed. \--------------------------------------------------------------------------------

Sponsors & Collaborators

  • Wu Jieping Medical Foundation

    collaborator OTHER

  • People's Hospital of Guangxi Zhuang Autonomous Region

    lead OTHER

Principal Investigators

  • Heming Lu, MS · People's Hospital of Guangxi Zhuang Autonomous Region

  • Heming Lu, MS · People's Hospital of Guangxi Zhuang Autonomous Region

  • Yun Mo, MS · People's Hospital of Guangxi Zhuang Autonomous Region

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-06-30
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01938105 on ClinicalTrials.gov